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The fusion reaction mediated by viral envelope glycoproteins proceeds through an ordered series of conformational changes in the envelope
glycoprotein. Fusion inhibitors have been developed that target glycoprotein subunits, arresting the reaction at different points in the process.
We report the development of a novel method for detecting viral glycoprotein-mediated fusion that is based on the principle of a-
complementation of h-galactosidase. The method is simple, accurate, has a high signal-to-noise ratio, is suited for high-throughput screening,
and does not require new transcription or protein synthesis. Cells expressing a viral envelope glycoprotein and the N-terminal a fragment of h-
galactosidase were mixed with cells expressing the C-terminal h-galactosidase fragment, CD4, CCR5, or CXCR4. Fusion was detected after
30 min and continued to increase to very high levels for more than 5 h. The assay was used to examine the temperature dependence of fusion
and the effect of coreceptor and glycoprotein density on inhibitor activity.
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Enveloped viruses enter target cells via a fusion reaction
mediated by the viral envelope glycoprotein (reviewed in
Chan and Kim, 1998; Eckert and Kim, 2001). Entry is
initiated when the surface component of the envelope
glycoprotein (SU) attaches to its receptor on the target cell
surface. In many enveloped viruses, attachment induces an
ordered series of conformational rearrangements in SU and
the transmembrane component (TM) that finally result in the
fusion of the lipid bilayer of the virus with the target cell,
either at the plasma membrane or in a low pH endosome.
HIV-1 attachment is mediated by the interaction of the
viral gp120 SU and its receptor on the target cell, CD4. This
binding induces a conformational change in gp120 that0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.11.012
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Carlsbad, CA 92008.exposes a binding site for a coreceptor, usually either of
the chemokine receptors CCR5 or CXCR4 (Berger et al.,
1999; Weiss, 2002). Coreceptor binding triggers rearrange-
ment of the gp41 TM from its compact native conformation
into an extended pre-hairpin intermediate, in which the
hydrophobic amino-terminal peptide of gp41 inserts into
the target cell plasma membrane (Doms and Moore, 2000).
The gp41 sequence contains two heptads repeats (HR1 and
HR2) that exist as separate triple helical coiled coils. After
attachment, the two domains are brought into proximity with
one another to form a single six-helix bundle in which the C-
terminal helices of HR2 fit into grooves on the outside of the
N-terminal coiled coil of HR1 (Chan et al., 1997; Weissen-
horn et al., 1996). Accumulation of these six helical bundles
allows the formation of a fusion pore that ultimately results
in fusion of the viral and cellular membranes (Melikyan et
al., 2000).
Virus entry is a promising target for the development of
novel therapeutics (reviewed in Eckert and Kim, 2001;
Moore and Stevenson, 2000). The glycoprotein and the
receptor proteins are exposed at the viral and cell surfaces,
and thus compounds that inhibit viral entry need not be
membrane soluble. In addition, the coreceptors are encoded
by cellular genes and so are not susceptible to mutations that
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entry inhibitors have been described and are in various stages
of development (reviewed in Blair et al., 2000; D’Souza et
al., 2000). These include (i) small molecule coreceptor
antagonists of CCR5 (Tak779 (Baba et al., 1999), AD101
(Trkola et al., 2002), and SCH-C (Strizki et al., 2001)) or
CXCR4 (AMD3100 (Schols et al., 1997)); (ii) chemokine
analogues with modified amino-termini (reviewed in Blan-
pain et al., 2002); (iii) the receptor mimic, soluble CD4
(Allaway et al., 1995); (iv) peptide fusion inhibitors T21
(Wild et al., 1992), T20 (Kilby et al., 1998), and C34 (Chan
et al., 1997; Jiang et al., 1993); and (v) neutralizing anti-
bodies that bind gp120 or gp41 (reviewed in Burton, 2002).
The peptide fusion inhibitors are derived from gp41 HR1
(T21) or HR2 (T20 and C34). These peptides are active at
nanomolar concentrations and are thought to block entry of
R5 and X4 isolates by targeting a transient intermediate
conformation of gp41 that forms upon CD4/coreceptor
contact (Chan et al., 1997; Jiang et al., 1993). They are
believed to bind HR1 or HR2 in the pre-hairpin intermediate,
where they interfere with conversion to the hairpin confor-
mation and thus block the formation of the six helical
bundles required to form the fusion pore (Chan and Kim,
1998, and references therein).
HIV-1 envelope glycoprotein-mediated entry and fusion
have been measured by several methods. These include
single replication cycle viruses that contain a reporter gene
(Connor et al., 1995), virions loaded with h-lactamase
(Cavrois et al., 2002), and cell–cell fusion assays (Line-
berger et al., 2002; Nussbaum et al., 1994). In cell fusion
assays, cells expressing the glycoprotein are mixed with cells
that express CD4 and CCR5 or CXCR4. Interaction of the
glycoprotein with the receptor and coreceptor on target cells
triggers fusion of the cells, which is quantitated by micro-
scopic counting of syncytia or quantitation of a reporter gene
transactivation.
Here we report the development of a novel cell–cell
fusion assay to measure viral glycoprotein-mediated fusion
that represents a significant advance over current methods.
The assay is based on the unique property of h-galactosidase
fragments to complement in trans, a phenomenon that has
been termed a-complementation (Ullmann et al., 1967, and
references therein). h-galactosidase is enzymatically active
as a tetramer and has the unique property that it can be
divided into two fragments, an N-terminal a peptide (amino
acids 1–80) and a C-terminal N fragment (amino acids 80–
1023) that complement in trans (Moosmann and Rusconi,
1996). The fragments are enzymatically inactive separately,Fig. 1. Demonstration of a-complementation. (A) 293T cells were transfected with
in triplicate samples 48 h posttransfection. (B) 293T cells transfected with pCMV-a
plasmid were mixed in triplicate with 293T cells stably expressing N alone, or N an
at 37jC for the indicated times after which h-galactosidase activity was measu
posttransfection. The cell mixtures were pelleted by low speed centrifugation and
washed and incubated at 37jC for the indicated times, after which h-galactosid
prepared as in B. The target cells stably expressed N and CXCR4. Where indicated
mixed, incubated, lysed, and h-galactosidase activity measured as in B.but when expressed together in cells, enzymatic activity is
reconstituted. a-Complementation of h-galactosidase was
initially found in Escherichia coli (Blakely et al., 2000;
Rossi et al., 1997) but can also occur in mammalian cells
(Moosmann and Rusconi, 1996), and has been used to study
protein–protein interactions (Rossi et al., 2000).
We applied the a-complementation principle to detect
viral glycoprotein-mediated fusion. This allowed measure-
ment of fusion without the need for preloading the target cell
with an enzymatic substrate or relying on downstream events
such as syncytia formation or reporter gene activity. In
addition, because the assay does not involve microscopic
enumeration of fusion events, it is objective and rapid. It
offers increased resolution of the timing of early fusion
events in comparison to many other common fusion assays,
with the exception of the h-lactamase-based assay. The
method can be generalized to other viral fusion systems or
other biological phenomena that involve cell–cell fusion and
is particularly well suited to high-throughput screening for
small molecule entry inhibitors of HIV or other enveloped
viruses. We have used the assay to understand parameters of
HIV fusion, temperature optima, and activities of fusion
inhibitors.Results
To demonstrate that a-complementation was active in
cells that support virus-mediated fusion, 293T cells were
transfected with expression vectors that expressed h-galac-
tosidase a (pCMVa) or N (pCMVN) (Moosmann and
Rusconi, 1996). For comparison, 293T cells were also trans-
fected with pCMV-h-gal, a vector expressing the full-length
enzyme. Cells transfected with a and N expression vectors
separately contained very low h-galactosidase activity. In
contrast, when the two vectors were cotransfected, they
complemented to yield highly active enzyme (Fig. 1A).
The a-complemented enzyme was nearly as active as the
native enzyme, resulting in h-galactosidase activity more
than 1000-fold above background levels.
To apply this phenomenon to the detection of viral
envelope glycoprotein-mediated fusion, 293T cells were
transiently cotransfected with vectors that expressed the
CXCR4-specific HIV-1 SF33 envelope glycoprotein, HIV-
1BRU Rev and h-galactosidase a. Two days posttransfection,
the cells were mixed with an equal number of 293T cells
transfected to express CD4, and h-galactosidase N. h-galac-
tosidase activity was then measured over the next 5 h (Fig.pCMV-a, pCMV-N, or pCMV-h-gal. h-galactosidase activity was measured
, Rev expression plasmid, and HIV-1SF33 envelope glycoprotein expression
d CD4. Each cell type alone, as well as the two cell mixtures, was incubated
red. (C) 293T cells transfected as in A were mixed in 1:1 ratios 2 days
fused with 50% (w/v) polyethylene glycol for 5 min. The cells were then
ase activity was measured. (D) Glycoprotein and a-expressing cells were
, CD4 was stably expressed and CCR5 was transiently expressed. Cells were
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mixing and continued to develop over time to a level 100-
fold higher than control cultures that lacked one of the
components. Artifactual explanations for the h-galactosidase
activity were ruled out by additional controls. For example,
polyethylene glycol (PEG)-mediated fusion of 293T cells
transiently expressing h-galactosidase a with 293T cells
expressing h-galactosidase N resulted in a signal that
appeared immediately after the PEG was removed, and
increased less than 3-fold over the next 4 h (Fig. 1C), an
increase that was probably due to new protein synthesis
rather than additional cell fusion. Thus, the a and N frag-
ments assemble very rapidly, and the increase in h-galacto-
sidase signal during the viral glycoprotein-mediated fusion
time course (Fig. 1B) is due to increased membrane fusion
over time. This accumulation of h-galactosidase activity was
CD4-dependent. When CD4 was not expressed on target
cells, h-galactosidase activity was close to background
levels. This finding demonstrated that there was no signifi-
cant amount of a-complementation that occurred due to a
and N proteins that had leaked from cells, and that there was
no significant amount of spontaneous cell–cell fusion. In
addition, the signal was not due to artifactual a-complemen-
tation that occurred upon lysis of cultures in the assay buffer.
Although free a and N are released upon lysis of cells, the
lysis buffer appeared to prevent postlysis association of the
two fragments, as well as postlysis dissociation of preformed
active enzyme complexes. Incubation of the cells before
mixing with the protein synthesis inhibitor cycloheximide
did not prevent a-complementation (data not shown). This
result demonstrated that complementing proteins exist in the
cells before fusion.
In principle, this method could be used to detect fusion
mediated by other viruses that contain fusogenic envelope
glycoproteins. To extend the findings to other viruses, we
tested glycoproteins from the R5 HIV-1 isolates ADA and
JR.FL, as well as glycoproteins from three other viruses,
vesicular stomatitis virus (VSV), human T cell leukemia
virus (HTLV), and amphotropic murine leukemia virus (A-
MuLV). The fusogenicity of the A-MuLV glycoprotein is
regulated by the length of its cytoplasmic tail (Rein et al.,
1994), so both the full-length glycoprotein and a cytoplasmic
tail deletion mutant were tested. 293T cells were cotrans-
fected with expression vectors for each glycoprotein, HIV-1
Rev, and the a fragment. The transfected cells were mixed
with target cells that stably expressed N, CD4, and CXCR4,
and transiently expressed CCR5 where indicated. The JR.FL,
ADA, and SF33 glycoproteins were all CD4-dependent and
required expression of the appropriate coreceptor (Fig. 1D).
The other three envelopes were all CD4-independent, as
expected. Full-length A-MuLV glycoprotein did not give a
signal but the cytoplasmic tail truncation was highly active
(about 10-fold more than JR.FL or ADA), demonstrating the
tight regulation of fusogenicity by the cytoplasmic tail. VSV-
G and HTLV-1 envelopes were also active in the assay,
although they only reached 10% of the activity of R5 HIV-1.Despite the fact that VSV-G entry occurs in low pH endo-
somes, acidification of the medium did not increase the
signal in this assay (data not shown).
Earlier reports (Golding et al., 2002; Melikyan et al.,
2000) have described pronounced temperature optima for
HIV-1 glycoprotein-mediated fusion. In these studies, fusion
was found to occur at 37jC, but not at lower temperatures
such as 22 or 31.5jC. At these reduced temperatures, Env is
thought to bind to CD4 and coreceptor and proceed to the
pre-hairpin conformation, where it becomes trapped. These
studies were done by manually counting the number of
syncytia formed over time at various temperatures. We were
interested to reexamine the temperature dependence of
fusion using the a-complementation assay to directly detect
the reaction. Cells expressing X4 SF33 or R5 ADA glyco-
proteins were tested in the fusion assay over a range of
temperatures for 4 h (Fig. 2A). Fusion occurred efficiently
from 23 to 40jC and was optimal at 30jC. This temperature
optimum was not due to differing efficiencies of assembly
of a and N over the temperature range because PEG-
mediated fusion over the same range of temperatures failed
to demonstrate significant temperature dependence (data not
shown). The activities of these two envelope glycoproteins
were also tested at several time points ranging from 1 to 4
h (Fig. 2B). Reactions performed on ice or at 20jC gave
undetectable signals over the time span of the experiment,
whereas reactions performed at both 31.5 and 37jC gave
high signals. For both envelope glycoproteins, reactions
incubated at room temperature resulted in undetectable
levels of fusion until they had been allowed to fuse for 4
h, at which point the signals rose slightly to approximately
8- to 10-fold above background.
The connection between temperature and peptide fusion
inhibitor activity was also examined. The fusion assay was
performed in parallel at the two temperatures that gave high
signals in the previous experiment, both in the absence and
presence of a low concentration of the peptide fusion
inhibitor T-20. The concentration of T-20 used (6.25 Ag/
ml) was determined empirically by assaying effectiveness of
the inhibitor at 37jC over a wide range of concentrations
(data not shown). The concentration selected was the high-
est concentration at which little to no effect of the com-
pound could be observed at 37jC. This is demonstrated in
Fig. 2C, where the effect of T-20 on the reaction at 37jC is
minimal and disappears after the reaction has proceeded for
2 h. The effect of the same concentration of T-20 on the
reaction performed at 31.5 jC is more dramatic and results
in a reduction in the progress of the fusion reaction to about
half of the signal generated by the reaction done in the
absence of T-20.
Several categories of fusion inhibitors were tested for
activity in the a-complementation fusion assay. IgG-CD4
immunoadhesion was tested for inhibitory activity by
performing parallel fusion reactions for 4 h at 37jC in the
absence and presence of 5-fold dilutions of inhibitors (Fig.
3A). The cells used were 293T cells transfected with the a
Fig. 2. Temperature effects. (A) 293Tcells expressing a, Rev, and SF33 or ADA glycoprotein were mixed with 293T target cells that stably expressedN, CXCR4,
and CD4 where indicated. The target cells mixed with the ADA envelope also transiently expressed CCR5. Cell mixtures were incubated at the indicated range of
temperatures and h-galactosidase activity was measured after 4 h. (B) Cells were prepared and mixed as in A and were then incubated at the indicated temperature
for the indicated times. CD4 was expressed on all target cells. (C) T-20 (6.25 Ag/ml) was added to the envelope-expressing cell before mixing.
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target cells were 293T cells stably expressing the N fragment
and CD4 (for the SF33 reactions) and 293T cells stably
expressing the N fragment and CD4 and transiently trans-
fected with low levels of CCR5 (for ADA and JR.FL
reactions, 200 ng pcDNA-CCR5 per 10 cm plate). sCD4-
IgG was capable of inhibiting both R5- and X4-tropic HIV
envelopes, though fairly high concentrations (20–100 Ag/
ml) were necessary to completely block fusion. Interesting-
ly, low concentrations of CD4-Ig appeared to enhance
fusogenicity of the SF33 envelope, while higher concen-
trations were inhibitory. This effect was likely due to an
sCD4-induced conformational change in the envelope gly-
coprotein that allowed it to more readily proceed to CXCR4
binding.
Four different small-molecule CCR5 inhibitors and one
CXCR4 inhibitor were tested for activity in the assay in a
similar fashion as for sCD4. The target cell for the CCR5
inhibitors was a HeLa cell line stably expressing the Nfragment, CD4, and low levels of CCR5. Reactions per-
formed with this cell line gave lower signals than reactions
performed with cells transiently transfected with CCR5, but
the stable cell line gave more consistent data in the assay
and was thus used here. The most potent CCR5 inhibitor in
the assay was TAK779, followed by the Merck compound,
Schering C, and finally the isomer of Schering C. AMD-
3100 was an active inhibitor of CXCR4-mediated fusion
over a similar range of concentrations. All four inhibitors
were active at concentrations extending down into the mid-
nanomolar range. Similar titration curves were generated for
two neutralizing antibodies against CD4 and CCR5, Leu3A,
and 2D7. Both antibodies were able to completely block
fusion at concentrations of 2–10 Ag/ml.
The titration curves that were generated (Fig. 3A) were
used to estimate the IC50 of each of the CCR5 inhibitors in
the fusion assay. Similar titration curves were generated for
each compound using pseudotyped single-cycle luciferase
reporter viruses, a well-established assay for Env-mediated
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Table 1
Comparison of IC50 values derived from the a-complementation assay and
single-cycle luciferase virus infection
Inhibitor Estimated IC50:
fusion assaya (nM)
Estimated IC50:
luciferase virus
inhibitionb (nM)
Merck compound 5 10
TAK779 10 8
Schering C 20 5
Isomer Schering C 100 2
a Values for IC50 were estimated from the curves shown in Fig. 3A.
b Inhibition curves were generated by adding each of the inhibitors to a
single-cycle infection with NL4-3 RELuc+ virions pseudotyped with the
ADA envelope. Values for IC50 were estimated as for the a-complementa-
tion assay.
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estimated as for the fusion assay and the values compared
(Table 1). Only one of the four inhibitors compared in this
fashion showed a large difference in IC50 as measured by
the two different assays, which might reflect differences
between membrane fusion and infection.
The effects of envelope expression levels as well as
coreceptor expression levels on the efficiency of fusion
inhibition were examined (Fig. 3B). In each case, cells were
transfected with decreasing amounts of the appropriate
expression vector, and multiple fusion assays were per-
formed both in the absence of an inhibitor and in the
presence of a high or low concentration of two different
inhibitors. In the case of CCR5 expression levels, low
concentrations of the inhibitor (that had little effect on fusion
when a large amount of CCR5 was transfected) showed an
inhibitory effect on fusion when smaller amounts of CCR5
were transfected, most noticeably between 8 and 200 ng.
Conversely, varying the envelope expression levels did not
result in a similar effect. Concentrations of the inhibitor that
inhibited fusion by about 15% when a large amount of Env
was expressed were only able to inhibit approximately the
same proportion of the signal as envelope expression de-
creased. FACS analysis of similarly transfected 293T cells
showed that transfection of increasing amounts of CCR5
expression plasmid resulted in higher levels of CCR5 ex-
pression per cell rather than an overall increase in the
proportion of transfected cells (data not shown).
Application of the assay to high-throughput inhibitor
screening was investigated using the method of Zhang et al.
(1999) to define a factor ZV, which is a measure of the
frequency with which false positive hits are detected over a
large number of measurements. The fusion reaction was
adapted to a microplate format and tested with an X4-tropicFig. 3. Activity of entry inhibitors. (A) Fusion inhibitors were serially diluted in D
microliters of each inhibitor were added to the envelope-expressing cell (sCD4)
antibodies) before cell mixing. All samples were incubated at 37jC for 4 h. (B) Serial
tested in the fusion assay both in the absence and presence of an inhibitor as indicated
of IC95 concentrations of entry inhibitors, and the resulting signal and background a
assay for high-throughput screening.glycoprotein in the absence or presence of IC95 of the X4
inhibitor AMD3100, and with an R5-tropic glycoprotein in
the absence or presence of IC95 of Merck’s small-molecule
R5 inhibitor (Fig. 3C). The mean and standard deviation of
the signal under each of the four conditions was calculated
and used to determine the ZV factor for each envelope. The
SF33 envelope resulted in a ZV of 0.58, while the ADA
envelope gave a value of 0.71. Each of these values is above
0.5, a figure that is considered sufficient for screening.
Further optimization, for example, by the use of automated
liquid handling robotics, should further increase this value.Discussion
We report here on the development of a novel assay based
on the principle of a-complementation of h-galactosidase for
the detection of viral envelope glycoprotein-mediated fusion.
The method has advantages over current methods with
respect to simplicity, accuracy, rapidity, and objectivity. It
allows examination of early events that occur during fusion
because it neither requires completion of any post-entry steps
in the viral life cycle, nor does it depend on de novo protein
synthesis of reporter genes. We found that HIV-mediated
fusion was optimal at reduced temperatures and that inhibitor
activity was dependent on coreceptor expression level,
consistent with the findings of Reeves et al. (2002).
The peptide inhibitors are an important class of fusion
inhibitors. These molecules act not on the native protein,
but on conformational intermediates formed upon CD4–
coreceptor binding (Chan et al., 1997; Jiang et al., 1993).
Low temperature increases their activity presumably by
stabilizing envelope glycoprotein conformational inter-
mediates, consistent with the earlier findings of Golding
et al. (2002). Because a-complementation was robust at the
suboptimal temperatures that expose these intermediates,
screening at reduced temperature could favor the identifi-
cation of small molecules that mimic the peptide inhibitors.
We did not find that fusion was trapped at 31.5jC. In our
assay, with the particular envelope glycoproteins used, we
rather found that fusion was optimal at reduced temper-
atures. Blocking of fusion required temperatures close to
22jC.
The inhibitors tested were generally of similar potency in
the fusion assay as compared to reporter virus infection
assays. This suggested that cell–cell fusion accurately mod-
els the fusion between virus and cell. Thus, the a-comple-
mentation assay is suitable for the identification of
compounds that target the envelope glycoprotein or theMSO (CCR5 inhibitors) or PBS (sCD4, AMD3100, and antibodies). Two
or the CD4–coreceptor-expressing cell (CCR5 inhibitors, AMD3100, and
dilutions of pcDNA-CCR5 or pSV-ADAwere transfected into 293Tcells and
. (C) 96 parallel fusion reactions were performed in the absence and presence
verages and standard deviations were used to quantify the effectiveness of the
A.U. Holland et al. / Virology 319 (2004) 343–352350HIV-1 receptor and coreceptor (CD4 and CCR5 or CXCR4).
Entry inhibitors that were active in the assay included CCR5
and CXCR4 antagonists, the peptide inhibitor T-20, and
antibodies against the receptor and coreceptor. Screening
with the assay could detect compounds that target any of the
three surface proteins. The target of active compounds can
then be distinguished in a secondary screen. Compounds can
be initially classified by whether they act on the envelope-
expressing cell or the CD4–coreceptor-expressing cell.
The simplicity and accuracy of the a-complementation
method are well suited to high-throughput screening for
fusion and entry inhibitors. Because fusion is detected
without relying on activation of a reporter gene and because
the complementing proteins preexist in the cells, compounds
that have global nonspecific effects on transcription, trans-
lation, or protein trafficking are not expected to confound the
analysis. This method can be applied to studies on other viral
glycoproteins in addition to HIV-1. Glycoproteins from
amphotropic MLV, VSV, and HTLV-1 were active in the
assay. In addition, the assay may be applicable for detecting
fusion in nonviral systems, such as the SNRPs that control
trafficking of intracellular vesicles in cells (Skehel and
Wiley, 1998).Materials and methods
Expression vectors and cell lines
Vectors for expression of the a fragment (pCMV-a,
formerly pSCTZ-a-N85), the omega fragment (pCMV-N,
formerly pSCTZ-omega), and full-length h-gal (pCMV-h-
gal, formerly pSCTZ) (Moosmann and Rusconi, 1996), the
HIV-1BRU expression vector, pRSV-Rev (Hope et al., 1990),
and envelope expression vectors (pSV-ADA and pSV-JRFL
(Deng et al., 1996), pCAGGS-SF33 (York-Higgins et al.,
1990), pCMV-G (Yee et al., 1994), pMLVampho (Deng et al.,
1996), pRR186 (Rein et al., 1994), and HTLV-1 env (Landau
et al., 1991)) were previously described. 293Tand HeLa cells
that stably expressed omegawere generated by cotransfection
with pCMV-N and pSV-hygro. Individual cell clones were
expanded and tested by transfection with pCMV-a or by
testing for activity in the a-complementation assay. N-
Expressing cell clones were transduced to express CD4
(Maddon et al., 1985) and CCR5 using pBABE retroviral
vectors (Morgenstern and Land, 1990; Onishi et al., 1996).
Transient expression of CD4 was achieved by transfection of
pcDNA-CD4 (Lee et al., 1999), and different levels of CCR5
were achieved by transfection of a 5-fold serial dilution of
pcDNA-CCR5 (Deng et al., 1996).
Measurement of a-complementation in human cell lines
Cells were cultured in DMEM/10% fetal bovine serum/
10 mM HEPES supplemented with penicillin and strepto-
mycin. Puromycin (1 Ag/ml) was included for passage ofretroviral vector-transduced cell lines. 293T cells (2.5 
106) were seeded in 10-cm dishes and transfected with 10
Ag pCMV-a, 10 Ag pCMV-N, or 10 Ag pCMV-h-gal
(Moosmann and Rusconi, 1996) using Lipofectamine
2000 (Invitrogen). After 48 h, the cells were removed from
plates with trypsin–EDTA (Gibco) and dispensed in tripli-
cate into thin-walled PCR strip-tubes (Phenix Research
Products) at 5  105 cells/tube. The cells were lysed in
100 Al lysis buffer (100 mM potassium phosphate, pH 7.8,
0.2% Triton X-100) and 10 Al was used for luminescent
measurement of h-galactosidase activity using GalactoStar
reagents (Applied Biosystems) and a TopCount microplate
luminometer.
For polyethylene glycol-mediated fusion, the cells were
transfected with a and N expression vectors. Two days later,
the cells were mixed at a 1:1 ratio (5  105 total cells/tube)
and pelleted by low speed centrifugation. The cells were
fused by replacing the medium with 100 Al of 50% (w/v)
polyethylene glycol (Sigma, average molecular weight:
3350) prewarmed to 37jC. After 5 min at room temperature,
the PEG was removed by washing twice with 4jC medium
and replaced with fresh medium. Following 37jC incuba-
tion for the indicated times, h-galactosidase activity was
measured as above.
Measurement of envelope glycoprotein-mediated fusion
293T cells (2.5  106) were transfected by lipofection
with pCMV-a, pRSV-Rev, and envelope expression vector
(7 Ag each). Target 293T or HeLa cells either stably
expressed the N fragment and the desired receptors, or were
lipofected with pCMV-N, pcDNA-CD4, and pcDNA-CCR5.
Two days posttransfection, cells were removed from culture
dishes with PBS/5 mM EDTA and adjusted to 5  106 cells/
ml in medium. Cells expressing the envelope glycoprotein
(50 Al) were mixed with an equal volume of target cells in
thin-walled PCR strip-tubes, lightly pelleted by a 10-s
centrifugation, and incubated in a water bath or a thermal
cycler (GeneAmp 9700, Applied Biosystems, or Master-
cycler Gradient, Eppendorf). For experiments in which anti-
bodies or inhibitors were included, these were added to the
appropriate target cell type before the cells were mixed. After
incubation for the indicated times, h-galactosidase activities
were measured as described above.Acknowledgments
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